<DOC>
	<DOCNO>NCT00230503</DOCNO>
	<brief_summary>- Compare safety four oral dos pradefovir 48 week treatment - Select dose pradefovir Phase 3 study</brief_summary>
	<brief_title>Dose-Ranging Study Pradefovir Patients With Compensated Hepatitis B</brief_title>
	<detailed_description>- Compare safety four oral dos pradefovir 48 week treatment - Compare antiviral activity four oral dos pradefovir adefovir dipivoxyl 48 week treatment - Select dose pradefovir Phase 3 study - Determine pharacokinetic profile four oral dos pradefovir</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Compensated chronic HBV Infection No prior treatment adefovir dipivoxil No interferon lamivudine treatment three month prior enrollment HBeAg positive negative HBV DNA viral load great 500,000 copy per mL ALT 1.2 10 time ULN Positive HIV , HCV , and/or HDV serology History renal tubular necrosis Serum creatinine great 2.0 mg/dl History organ transplant use immunosuppresive drug Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hepatitis B , Chronic</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Pradefovir Mesylate</keyword>
	<keyword>Adefovir Dipivoxyl</keyword>
</DOC>